Talazoparib and Avelumab in Participants With Metastatic Renal Cell Carcinoma

NCT04068831 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

18

Enrollment

OTHER

Sponsor class

Conditions

Metastatic Renal Cell Carcinoma
Fumarate Hydratase Deficient Renal Cell Carcinoma
Succinate Dehydrogenase Deficient Renal Cell Carcinoma

Interventions

DRUG: Talazoparib
DRUG: Avelumab

Sponsor

Memorial Sloan Kettering Cancer Center